Search results: (10000)
News Familial Hypercholesterolemia and COVID-19: Connections and Risks
Patients with familial hypercholesterolemia (FH) likely have a higher risk of COVID-19 complications both in the acute phase of the infection and for a relatively long period after its occurrence.
News Metabolic Effect of Telmisartan and Candesartan in Kidney Transplant Patients
Increasing cardiovascular risk from complex causes warrants a comprehensive intervention. A prospective randomized crossover study compared the effects of telmisartan and candesartan on lipid and glucose metabolism in kidney transplant patients.
News Cariprazine − a Cardiometabolically Friendly Antipsychotic
Part of the 63rd Czech-Slovak Psychopharmacological Conference, held online from January 15−16, 2021, featured a lecture by Prof. MUDr. Jiří Masopust, Ph.D., from the Psychiatric Clinic of the Faculty of Medicine, Charles University and University Hospital Hradec Králové, titled “Cariprazine: a Cardiometabolically Friendly Antipsychotic”.
News Is the Quality of Life for Patients with Atrial Fibrillation and Heart Failure Comparable When Treated with Bisoprolol and Digoxin?
The British RATE-AF study, published in December 2020 in the JAMA journal, compared the impact on improving the quality of life in patients with permanent atrial fibrillation (AF) and symptoms of heart failure when administering bisoprolol and low-dose digoxin.
News Trastuzumab Deruxtecan in Patients with HER2+ Metastatic Breast Cancer
Last year, results of studies published in the Lancet journal demonstrated a significant clinical benefit of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer (mBC) pre-treated with anti-HER2 therapy, in the 2nd or later lines of treatment compared to trastuzumab emtansine (DESTINY-Breast03 study, second interim overall survival analysis) and after failure of trastuzumab emtansine compared to physician's choice of therapy (DESTINY-Breast02 study).
News Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis
Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV (chemotherapy-induced nausea and vomiting) and, using recommended antiemetic prophylaxis, this problem has been relatively well managed. However, the incidence and impact of nausea are underreported. We present the results of an observational study that evaluated the incidence of nausea in patients undergoing chemotherapy.
News Do ACE Inhibitors Have a Protective Effect in People with COVID-19?
Although the COVID-19 pandemic has not lasted even a year, a number of studies have already been processed, examining the influence of various factors on the morbidity and mortality of patients. The presented meta-analysis investigated the influence of ACE inhibitors on the mortality of patients with this disease.
News Metamizole in the Treatment of Acute Postoperative Pain
In many countries, metamizole is considered a first-choice non-opioid analgesic. The analysis presented below, published in the Cochrane Database of Systematic Reviews, examined the efficacy and safety of metamizole in the treatment of acute postoperative pain.
News 6 Possible Benefits of Adding Empagliflozin to Metformin
Currently, there is intense discussion about the advantages of sodium-glucose co-transporter 2 inhibitors (SGLT2i, also known as gliflozins) in terms of their cardio and nephroprotective properties. Below, we summarize the proven beneficial effects specifically associated with adding empagliflozin to metformin and mention the indications for empagliflozin, which are reimbursed.
News EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction
Prague, March 8, 2022 – Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had previously approved empagliflozin for the treatment of patients with chronic heart failure with reduced ejection fraction and for the treatment of adults with inadequately controlled type 2 diabetes. The drug was developed by Boehringer Ingelheim.
News Shared Decision-Making on Kidney Function Replacement
Peritoneal dialysis (PD) is not a new development, but its significance is becoming increasingly recognized. Until recently, we may not have fully appreciated its value, but in light of the global threat posed by the current pandemic, its importance is starkly clear. PD is an accessible solution designed for home care and allows patients to avoid visits to healthcare facilities to some extent.
News Shared Decision Making Plays an Important Role in Dialysis
Peritoneal dialysis is very effective and comfortable for patients, yet it is used relatively little in the Czech Republic. Are we giving enough room to patients' preferences?
News Teriflunomide and Pregnancy Planning
The authors of the article published last year in Multiple Sclerosis Journal present data regarding experiences with the use of teriflunomide during pregnancy.
News Safety and Tolerance of Metamizole in Postoperative Analgesia in Children
Due to the potential serious side effects of metamizole, the use of this drug in children is often a topic of discussion. Therefore, a prospective multicenter observational non-interventional post-marketing safety study aimed to evaluate the safety of using metamizole in children, with an emphasis on hemodynamic, anaphylactic, or respiratory reactions and agranulocytosis.
News Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease – Prospective ELEGANCE Study
Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The German team behind the ELEGANCE study aimed to gather available data and analyze the efficacy and safety of this modality in the long-term treatment of PD.
News Relationship Between Mortality and Use of Statins or RAAS Inhibitors After Aortic Valve Replacement
The impact of prescribed medication after transcatheter aortic valve replacement (TAVR) has not been precisely assessed to date. A recently published retrospective analysis of clinical practice data from patients who underwent TAVR aimed to assess the potential benefit of using statins and renin-angiotensin-aldosterone system (RAAS) inhibitors.
News Subcutaneous zilucoplan – the end of necessary “trips” to the hospital for myasthenia gravis patients?
A study recently published in Lancet Neurology demonstrated the efficacy and safety of the subcutaneously administered complement component C5 inhibitor – zilucoplan – in the treatment of myasthenia gravis (MG). This drug has the potential to alleviate the severity of this disease and improve the quality of life of patients.
News Three times on the topic of therapeutic cannabis usage possibilities – case studies from Czech practice
The following case studies from real Czech practice describe three cases of patients with various diagnoses, indicated for cannabis extract administration. In the first case, there was significant pain relief in an elderly patient with vertebrogenic pain syndrome. The second case study outlines the possibilities of using cannabis extract in the treatment of neuropathic pain in a polymorbid elderly patient. The final contribution describes the effect of this preparation in palliative therapy of an oncological patient.
News Off-label use of eye drops containing bromfenac in the treatment of cystoid macular edema in the only seeing eye of a complex patient – case report
The following case report discusses the effect of repeated use of an ophthalmic preparation containing bromfenac in a patient with recurrent cystoid macular edema (CME) in the only seeing eye with advanced glaucoma. The patient has undergone more than 15 eye surgeries or procedures, has been treated for glaucoma since 2005, and has multiple intolerances to eye drops and polymorphic problems, which she attributes to the application of the drops. The dominant personality trait is an anxious approach, which, together with the complicated findings in the only seeing eye, narrows the selection of therapeutic options.
News Telmisartan, amlodipine, and chlorthalidone in a low-dose fixed triple combination – better control of target blood pressure values?
The secondary analysis of the TRIUMPH study, recently published in JAMA Cardiology, is likely the first published assessment of time spent in the target blood pressure (BP) range during antihypertensive treatment. This parameter was assessed in patients with moderate hypertension using a low-dose triple combination of antihypertensives (telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg) compared to usual care.
News Doc. Milan Sova: AAT substitution is available to all indicated patients. It is therefore crucial to now educate about the necessity of regular treatment
Alpha-1-antitrypsin deficiency (AATD) is one of the most common genetic disorders in adults. It is usually associated with the early development of chronic obstructive pulmonary disease (COPD) or liver damage. We discuss how modern substitution therapy can change patients' prognosis and when to consider this diagnosis with the head of the Clinic of Pulmonary Diseases and Tuberculosis at Masaryk University Faculty of Medicine and Brno University Hospital, Doc. MUDr. Milan Sova, Ph.D.
News Treatment Options for Advanced Parkinson's Disease Using Medical Devices (DAT)
A new treatment option for advanced Parkinson's disease (PD) using medical devices (DAT − device-aided therapy) is the intestinal infusion gel containing levodopa, entacapone, and carbidopa (LECIG). An article published in 2022 in the journal Therapeutic Advances in Neurological Disorders provides an overview of current DAT modalities in PD patients and presents LECIG as the latest extension of options in this area.